JP2004501204A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004501204A5 JP2004501204A5 JP2002505026A JP2002505026A JP2004501204A5 JP 2004501204 A5 JP2004501204 A5 JP 2004501204A5 JP 2002505026 A JP2002505026 A JP 2002505026A JP 2002505026 A JP2002505026 A JP 2002505026A JP 2004501204 A5 JP2004501204 A5 JP 2004501204A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- peptide
- tyrosine
- antibody fragment
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 26
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 9
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 102000014914 Carrier Proteins Human genes 0.000 claims description 3
- 108010078791 Carrier Proteins Proteins 0.000 claims description 3
- 238000004132 cross linking Methods 0.000 claims description 3
- 230000002163 immunogen Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 230000000069 prophylactic effect Effects 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims description 2
- 229960000814 tetanus toxoid Drugs 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 8
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000013060 biological fluid Substances 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 2
- OQALFHMKVSJFRR-UHFFFAOYSA-N dityrosine Chemical compound OC(=O)C(N)CC1=CC=C(O)C(C=2C(=CC=C(CC(N)C(O)=O)C=2)O)=C1 OQALFHMKVSJFRR-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000178 monomer Substances 0.000 claims 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 claims 1
- 241000237988 Patellidae Species 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 229910001431 copper ion Inorganic materials 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 239000013638 trimer Substances 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21477900P | 2000-06-28 | 2000-06-28 | |
| US24217700P | 2000-10-23 | 2000-10-23 | |
| PCT/AU2001/000786 WO2002000245A1 (en) | 2000-06-28 | 2001-06-28 | Neurotoxic oligomers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004501204A JP2004501204A (ja) | 2004-01-15 |
| JP2004501204A5 true JP2004501204A5 (https=) | 2009-12-17 |
Family
ID=26909346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002505026A Pending JP2004501204A (ja) | 2000-06-28 | 2001-06-28 | 神経毒オリゴマー |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7618634B2 (https=) |
| EP (1) | EP1296705B1 (https=) |
| JP (1) | JP2004501204A (https=) |
| CN (2) | CN1450908A (https=) |
| AU (2) | AU6882801A (https=) |
| CA (1) | CA2413354C (https=) |
| DK (1) | DK1296705T3 (https=) |
| ES (1) | ES2389811T3 (https=) |
| NZ (1) | NZ523428A (https=) |
| WO (1) | WO2002000245A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) * | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| WO2006014638A2 (en) * | 2004-07-19 | 2006-02-09 | The General Hospital Corporation | ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS |
| US9335331B2 (en) * | 2005-04-11 | 2016-05-10 | Cornell Research Foundation, Inc. | Multiplexed biomarkers for monitoring the Alzheimer's disease state of a subject |
| RU2432362C2 (ru) | 2005-11-30 | 2011-10-27 | Эбботт Лэборетриз | Моноклональные антитела и их применения |
| PL2289909T3 (pl) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał |
| DK1984344T3 (da) | 2005-12-29 | 2013-01-14 | Lexicon Pharmaceuticals Inc | Multicykliske aminosyrederivater og fremgangsmåder til anvendelse heraf |
| US8455626B2 (en) * | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
| US20090246191A1 (en) * | 2007-10-11 | 2009-10-01 | University Of Tennessee Research Foundation | Preparation of Purified Covalently Cross-linked Abeta Oligomers and Uses Thereof |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| WO2011064225A1 (en) * | 2009-11-24 | 2011-06-03 | Probiodrug Ag | Novel diagnostic method for the diagnosis of alzheimer's disease or mild cgnitive impairment |
| JP2013521233A (ja) | 2010-02-25 | 2013-06-10 | ヤンセン アルツハイマー イミュノセラピー | Ａβを標的とする免疫療法のＰＥＴモニタリング |
| ES2684475T3 (es) | 2010-04-15 | 2018-10-03 | Abbvie Inc. | Proteínas que se unen a beta amiloide |
| CN103298833B (zh) | 2010-08-14 | 2015-12-16 | Abbvie公司 | β淀粉样蛋白结合蛋白 |
| US20120321694A1 (en) * | 2010-10-27 | 2012-12-20 | Daniel Larocque | Compositions and uses |
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| KR102759003B1 (ko) * | 2018-05-15 | 2025-01-23 | 보오슈 앤드 롬 인코포레이팃드 | 수 추출 가능한 안과용 디바이스 |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
| DE102019129221B4 (de) | 2019-10-29 | 2022-05-12 | Chiracon Gmbh | Verfahren zur Synthese von DOPA mit einer fotolabilen Schutzgruppe und Zwischenprodukten zu dessen Herstellung |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| KR20230128606A (ko) * | 2022-02-28 | 2023-09-05 | 경상국립대학교산학협력단 | 티로신을 유효성분으로 함유하는 알츠하이머병의 예방, 개선 또는 치료용 조성물 |
| CN117024554A (zh) * | 2023-05-30 | 2023-11-10 | 中国人民解放军空军军医大学 | 一种Aβ1-42寡聚体存储液的制备方法及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863735A (en) * | 1985-02-19 | 1989-09-05 | Massachusetts Institute Of Technology | Biodegradable polymeric drug delivery system with adjuvant activity |
| US5688651A (en) * | 1994-12-16 | 1997-11-18 | Ramot University Authority For Applied Research And Development Ltd. | Prevention of protein aggregation |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
-
2001
- 2001-06-28 ES ES01947033T patent/ES2389811T3/es not_active Expired - Lifetime
- 2001-06-28 JP JP2002505026A patent/JP2004501204A/ja active Pending
- 2001-06-28 EP EP01947033A patent/EP1296705B1/en not_active Expired - Lifetime
- 2001-06-28 DK DK01947033.5T patent/DK1296705T3/da active
- 2001-06-28 NZ NZ523428A patent/NZ523428A/en not_active IP Right Cessation
- 2001-06-28 CN CN01813312A patent/CN1450908A/zh active Pending
- 2001-06-28 US US10/312,437 patent/US7618634B2/en not_active Expired - Fee Related
- 2001-06-28 CN CN2008101298934A patent/CN101411876B/zh not_active Expired - Fee Related
- 2001-06-28 WO PCT/AU2001/000786 patent/WO2002000245A1/en not_active Ceased
- 2001-06-28 AU AU6882801A patent/AU6882801A/xx active Pending
- 2001-06-28 CA CA2413354A patent/CA2413354C/en not_active Expired - Fee Related
- 2001-06-28 AU AU2001268828A patent/AU2001268828C1/en not_active Ceased
-
2009
- 2009-05-14 US US12/466,094 patent/US8318171B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004501204A5 (https=) | ||
| US8318171B2 (en) | Neurotoxic oligomers | |
| CA2501945A1 (en) | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof | |
| JP2006519762A5 (https=) | ||
| AU2011281247B2 (en) | Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition | |
| WO2006031825A3 (en) | Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof | |
| RU2007145052A (ru) | Композиции пептидного конъюгата и способы для профилактики и лечения болезни альцгеймера | |
| JP2005500389A5 (https=) | ||
| AU2001268828A1 (en) | Neurotoxic oligomers | |
| WO2002043660A3 (en) | Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment | |
| WO2002062824A3 (en) | Method of treating amyloid ? precursor disorder | |
| RU2001130068A (ru) | Антиидиотипические антитела к антителам, которые ингибируют связывание иммуноглобулина с его высокоаффинным рецептором | |
| Kou et al. | Combined treatment of Aβ immunization with statin in a mouse model of Alzheimer's disease | |
| CN119504936A (zh) | 赖氨酸l-苯乳酸化修饰半抗原、人工抗原及其制备方法和应用 | |
| CN119504937A (zh) | 赖氨酸苯乙酰化修饰半抗原、人工抗原及其制备方法和应用 | |
| Bearn et al. | The impact of naloxone/lofexidine combination treatment on the opiate withdrawal syndrome | |
| RU2353389C2 (ru) | Способы лечения болезни альцгеймера с использованием антител, направленных против пептида амилоида-бета, и их композиций | |
| CA2468496A1 (en) | Ilk inhibitors for the treatment of renal disease | |
| CN119504938A (zh) | 赖氨酸2-羟基苯乙酰化修饰半抗原、人工抗原及其制备方法和应用 | |
| RU2007145527A (ru) | Применение связывания антитело-лиганд для описания заболевания | |
| Hentschel et al. | Stroke in elderly patients-Prevention and therapy has been proven effective in every age | |
| WO2003034977A3 (en) | Combination therapy for treating disease | |
| HK1131745B (en) | Neurotoxic oligomers | |
| Shimao et al. | Renal excretion of calcium. phosphate and protein in the first week of life | |
| Genetet et al. | ELSA PTH: A new immunoradiometric assay for the determination of the intact human parathormone |